2nd ed. 2019 Edition
by Andrew J. Krentz (Editor), Christian Weyer (Editor), Marcus Hompesch (Editor)
This book aims to aid the selection of the most appropriate methods
for use in early phase (1 and 2) clinical studies of new drugs for
diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related
cardiometabolic disorders.
Clinical research methods to assess
the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g.
the euglycemic clamp technique, have become well-established in
proof-of-mechanism studies. However, selection of the most appropriate
techniques is by no means straightforward. Moreover, the application of
such methods must conform to the regulatory requirements for new drugs.
This
book discusses the need for new pharmacotherapies for diabetes, obesity
and NAFLD and the molecular targets of drugs currently in development.
Emerging technologies including functional imaging, circulating
biomarkers and omics are considered together with practical and ethical
issues pertaining to early phase clinical trials in subjects with
cardiometabolic disorders.
Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease
is of interest to biomedical scientists, pharmacologists, academics
involved in metabolic research and clinicians practicing in these
specialties.
